GE HealthCare launches Allia IGS Pulse after FDA 510(k) clearance

GE HealthCare (Nasdaq: GEHC) has stepped into a new era of cardiovascular imaging by announcing the FDA 510(k) clearance of Allia IGS Pulse, a significant addition to its Image Guided System (IGS) portfolio. The Allia IGS Pulse promises exceptional imaging, fine-tuned to cater to varying patient sizes while ensuring optimal dosages during complex cardiology procedures.

Addressing Global Cardiovascular Disease Prevalence

With Cardiovascular Disease (CVD) recognized as the leading global cause of death, the demand for minimally invasive surgery and evolved cardiology procedures is on the rise. GE HealthCare remains at the forefront of this evolution, driving quality care with optimized workflows, image guidance technologies, and outstanding image quality.

Designed for Interventionalists’ Needs

Survey results indicate that nearly half of interventional procedures occur in settings where access to display and user interface is suboptimal. Allia IGS Pulse rises to the occasion, offering a customized workspace tailored to operators’ preferences. Unique features include its pioneering monopolar x-ray tube for image capture, ensuring silent operations and allowing for steep angulation to better comprehend coronary artery anatomy.

Quality Imaging for Varied Patient Profiles

Acknowledging the importance of image quality and dose management, the Allia IGS Pulse system shines with unparalleled image clarity, especially in patients having a BMI above 30. Further enhancing its usability, the system’s AutoRight PLUS integrates real-time optimization of seven parameters, including the Focal Spot Shape. This AI-empowered adjustment liberates clinicians from manual tuning during procedures, fostering a dedicated focus on patient care.

Enhanced image quality with GE HealthCare’s FDA-approved Allia IGS Pulse. Photo courtesy of Business Wire/GE HealthCare.

Testimonials from the Frontlines

The efficacy of Allia IGS Pulse has been vouched for by renowned Interventional Cardiologists at Clinique Pasteur, Toulouse. Dr. Nicolas Dumonteil praised the system’s imaging quality, noise reduction, and adaptability. Likewise, Dr. Raphaël Philippart stressed its unmatched clarity, especially during intricate angioplasties.

GE HealthCare’s Commitment to Excellence

Arnaud Marie, General Manager of Interventional for GE HealthCare, conveyed the brand’s enthusiasm for Allia IGS Pulse. By addressing challenges consistently flagged by clinicians, GE HealthCare champions a user-centric design that accentuates patient care.

To further intrigue the cardiology community, GE HealthCare plans to feature the Allia IGS Pulse at the Transcatheter Cardiovascular Therapeutics 2023 conference (TCT).